Publications by authors named "L Gilstrap"
Article Synopsis
- Accountable care organizations (ACOs) aim to enhance healthcare quality and lower costs for heart failure patients, but there’s limited understanding of admission rate variations across different ACOs.
- A study of over 1.2 million heart failure patients revealed significant differences in acute admission rates among 467 ACOs, with a median of 87 admissions per 100 people, highlighting that 13% performed better while 14% performed worse than average.
- ACOs that had better performance generally had fewer Black beneficiaries and were independent, while those that fared worse tended to be large, hospital-affiliated, and located in the Northeast with fewer primary care providers.
Purpose: To evaluate the safety, efficacy, and outcomes of outpatient intravenous diuresis in a rural setting and compare it to urban outcomes.
Methods: A single-center study was conducted on 60 patients (131 visits) at the Dartmouth-Hitchcock Medical Center (DHMC) from 1/2021-12/2022. Demographics, visit data, and outcomes were collected and compared to urban outpatient IV centers, and inpatient HF hospitalizations from DHMC FY21 and national means.
Cystadenoma arising from the larynx is a rare benign minor salivary gland tumor that can show mucinous or papillary morphology. The epithelial lining of the salivary gland tumor can present with oncocytic features, which is attributed to an increased number of mitochondria. We present a rare case of oncocytic papillary cystadenoma (OPC) of the larynx which has a combination of these features.
View Article and Find Full Text PDFAims: To optimize guideline-directed medical therapy for heart failure, patients may require the initiation of multiple neurohormonal antagonists (NHAs) during and following hospitalization. The safety of this approach for older adults is not well established.
Methods And Results: We conducted an observational cohort study of 207 223 Medicare beneficiaries discharged home following a hospitalization for heart failure with reduced ejection fraction (HFrEF) (2008-2015).
Article Synopsis
- Tafamidis was approved for treating hereditary and wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) in May 2019, based on the ATTR-ACT clinical trial findings.
- A retrospective study analyzed the prescription patterns of tafamidis among 430 patients with ATTRwt-CM from May 2019 to December 2020, finding that 100% were prescribed within 9 months of diagnosis.
- Key factors influencing the prescription included being age 65 or older, male, having heart failure/cardiomyopathy, and undergoing specific heart imaging tests, indicating a need for further studies on real-world outcomes for these patients.